Zobrazeno 1 - 10
of 30
pro vyhledávání: '"S, Kafonek"'
Publikováno v:
The American journal of cardiology. 87(5)
The 6-week efficacy and safety of atorvastatin versus simvastatin was determined during a 54-week, open-label, multicenter, parallel-arm, treat-to-target study. In all, 1,424 patients with mixed dyslipidemia (triglyceride 200 to 600 mg/dl [2.26 to 6.
Publikováno v:
The American journal of medicine. 104(2)
To assess the lipid-lowering effects and safety of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia.We performed a randomized, open-label, parallel-design, active-controlled, study in eight centers in
Publikováno v:
The American journal of cardiology. 81(5)
The objective of this multicenter, randomized, open-label, parallel-group, 8-week study was to evaluate the comparative dose efficacy of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor atorvastatin 10, 20, 40, and 80 mg compar
Publikováno v:
Atherosclerosis Supplements. 2:95-96
Publikováno v:
Diabetes Research and Clinical Practice. 50:319-320
Autor:
S. Kafonek, Peter B. Jones, Robert H. Knopp, William Insull, Michael H. Davidson, Donald B. Hunninghake, L. Lohrbauer
Publikováno v:
Atherosclerosis. 144:28-29
Publikováno v:
Atherosclerosis Supplements. 2:87
Autor:
S. Kafonek
Publikováno v:
American Journal of Hypertension. 11:75A
Publikováno v:
Clinical chemistry. 35(3)
Using radial immunodiffusion, we measured apolipoprotein B (apoB) concentrations in fresh plasma from 216 hyperlipidemic male subjects and in aliquots of the same plasma stored at -70 degrees C for 22 months. At the time of sampling, 112 were being t
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.